We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

109 hedge funds and large institutions have $446M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 27 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

78% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 27

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

3% more funds holding

Funds holding: 106 → 109 (+3)

5% less capital invested

Capital invested by funds: $470M → $446M (-$24.9M)

Holders
109
Holders Change
+3
Holders Change %
+2.83%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
20
Increased
48
Reduced
27
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$26.6M
2
RCMNY
Rubric Capital Management (New York)
New York
+$13.6M
3
State Street
State Street
Massachusetts
+$9.48M
4
OCAM
Onex Canada Asset Management
Ontario, Canada
+$5.66M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.83M

Top Sellers

Rank Fund Capital Flow
1
FFM
Fairmount Funds Management
Pennsylvania
-$21.9M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$10.2M
3
DM
Deerfield Management
New York
-$7.73M
4
GPP
Great Point Partners
Connecticut
-$7.56M
5
BlackRock
BlackRock
New York
-$5.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Scotia Capital
Ontario, Canada
$2.73M – – –
AAA
27
Affinity Asset Advisors
New York
$2.21M -$3.29M -443,358 -59%
Rafferty Asset Management
28
Rafferty Asset Management
New York
$2.17M +$1.1M +148,802 +100%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.86M +$223K +30,076 +13%
Goldman Sachs
30
Goldman Sachs
New York
$1.76M +$467K +62,965 +35%
PAMP
31
Polar Asset Management Partners
Ontario, Canada
$1.73M -$843K -113,600 -32%
Charles Schwab
32
Charles Schwab
California
$1.61M +$210K +28,274 +15%
Vontobel Holding
33
Vontobel Holding
Switzerland
$1.44M +$1.46M +197,278 New
SAM
34
Sectoral Asset Management
Quebec, Canada
$1.35M +$1.37M +185,278 New
Barclays
35
Barclays
United Kingdom
$1.3M +$621K +83,695 +88%
AllianceBernstein
36
AllianceBernstein
Tennessee
$1.18M +$864K +116,386 +259%
Swiss National Bank
37
Swiss National Bank
Switzerland
$1.1M -$63.8K -8,600 -5%
BFS
38
Baskin Financial Services
Ontario, Canada
$1.05M – – –
IC
39
Ikarian Capital
Texas
$1.02M -$2.31M -310,841 -69%
Citigroup
40
Citigroup
New York
$957K -$63.8K -8,602 -6%
CCMU
41
Cheyne Capital Management (UK)
United Kingdom
$926K +$943K +127,090 New
JP Morgan Chase
42
JP Morgan Chase
New York
$914K +$627K +84,438 +207%
Fisher Asset Management
43
Fisher Asset Management
Washington
$867K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$736K +$60.3K +8,122 +9%
UBS Group
45
UBS Group
Switzerland
$735K +$554K +74,704 +287%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$644K +$6.66K +897 +1%
LPL Financial
47
LPL Financial
California
$576K – – –
AI
48
Atom Investors
Texas
$532K +$72.8K +9,812 +16%
AA
49
ALPS Advisors
Colorado
$522K +$166K +22,434 +46%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$477K +$140K +18,877 +41%
1
2
3 4 5

PNT Hedge Fund Activity: Q4 2022 in Review

109 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2022, worth a combined $446M — down 5.3% from $470M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PNT positions and 17 closed out — a net gain of 3 holders — while 48 added to existing stakes and 27 trimmed.

The largest buyer was BVF Inc, adding an estimated $26.6M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $21.9M sold.

  • 109 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2022, up from 106 in Q3 2022.
  • Funds reported $446M of POINT Biopharma Global Inc. Common Stock stock for Q4 2022, down 5.3% quarter-over-quarter.
  • 20 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2022 and 17 closed out, a net change of +3 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2022 was BVF Inc, an estimated $26.6M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2022 was Fairmount Funds Management, an estimated $21.9M sold.

Based on aggregated 13F filings for Q4 2022.